An observational study in GERD, sponsored by Universitair Ziekenhuis Brussel. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Universitair Ziekenhuis Brussel · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Gastroesophageal Reflux with a site in Belgium — 2 open to participants now, 3 under way, none of them phase 3. Gastroesophageal Reflux · Belgium.
Among the 54 studies in Gastroesophageal Reflux with a site in Belgium, this one is one of 3 that started in 2023, is one of 8 observational ones, and was the 54th registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →2 of the 54 studies in Gastroesophageal Reflux with a site in Belgium are open now. Recruiting first, the newest first:
United Pharmaceuticals · Sites in Belgium, France, Greece and 1 more country
Ages 2 wk–4 mo
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 180 across 349 observational studies indexed under Gastroesophageal Reflux.
Median enrollment 67 across the 45 interventional studies, 127 across the 7 observational. Of the 44 that completed or were terminated, 15 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 54 have an industry lead sponsor. The 10 most frequent:
Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.
Universitair Ziekenhuis Brussel has 3 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastroesophageal Reflux with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04358146United PharmaceuticalsStudy on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR) | 2026-12-03 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies in Gastroesophageal Reflux with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Commonly, in clinical practice an automated analysis of pH-MII tracings is obtained.
All pH-MII performed in UZ Brussel are already reviewed manually according to the Wingate con-sensus and interpreted according to the Lyon consensus. In this study, we will prospectively categorise the reasons for discarding reflux episodes identified by automated analysis during the manual review according to the Wingate consensus, as well as the impact on different parameters related to the interpretation of pH-MII. Based on comments received to our retrospective study, we will evaluate possible confounders to the interpretation, including the indication for referral for pH-MII, symptom severity, use of PPI during pH-MII.
All patients referred for pH-MII are eligible.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Questionnaires
FSSG \& BEDQ
Statistical difference in the GERD categorisation
the statistical difference in the distribution of GERD categorisation between automated vs. manual review of the pH-MII tracings
Time frame: During baseline visit
The analysis of the influence of different parameters on application of the Wingate criteria: including the Indication for referral with further classification into predominant oesophageal and extra-oesophageal symptoms;
Time frame: During baseline visit
The analysis of the influence of different parameters on application of the Wingate criteria: including the GERD Symptom Severity;
Time frame: During baseline visit
The analysis of the influence of different parameters on application of the Wingate criteria: including the patient being on or off PPI;
Time frame: During baseline visit
The analysis of the influence of different parameters on application of the Wingate criteria: including MNBI (obtained by automated analysis or manually calculated);
Time frame: During baseline visit
Presence of significant correlations between censored episodes and pH-MII parameters
Correlations including: * Acid exposure time; * Total number of reflux episodes identified by impedance monitoring; * MNBI; * PSPWI.
Time frame: During baseline visit
Impact of the Wingate criteria on The number of PSPW;
Time frame: During baseline visit
Impact of the Wingate criteria on The number of symptoms associated with an impedance episode.
Time frame: During baseline visit
Impact of the Wingate criteria on the number of impedance episodes with or without acidic reflux
Time frame: During baseline visit
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Apr 2026, 30 months after the start.
Of 95 non-industry observational studies under Gastroesophageal Reflux, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 167. This study's planned 30 months is below that.
Counting every sponsor, half of 117 studies reached it within 45 months; a quarter within 17 and three quarters within 134.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitair Ziekenhuis Brussel →